Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8398364 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6302878 | 0.86 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL4576392 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL4577762 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8397305 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6308147 | 0.86 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL6300839 | 0.86 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL8720980 | 0.85 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL8073215 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8726248 | 0.84 | PTGS2 (0.72) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | claimed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | claimed |
| US-5866596-A | DRUGS WITH ANTIINFLAMMATORY AND ANALGESIC PROPERTIES. | LABORATORIES UPSA (FR) | 1999-02-02 | — | — | US | claimed |
| US-20260027079-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | EPM IP INC (US) | 2026-01-29 | — | — | US | disclosed |
| CN-118831076-A | Cannabinoid acid ester compositions and uses thereof | EPM (IP)公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-113840598-B | Cannabinoid acid ester compositions and uses thereof | EPM (IP)公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20230202964-A1 | CANNABIGEROLIC ACID (CDGA) DERIVATIVES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-06-29 | — | — | US | disclosed |
| US-20230192588-A1 | CANNABIDIOLIC ACID (CBDA) DERIVATIVES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-06-22 | — | — | US | disclosed |
| EP-4161900-A1 | CANNABIDIOLIC ACID (CBDA) DERIVATIVES AND USES THEREOF | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2023-04-12 | — | — | EP | disclosed |
| US-20220151972-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | EPM (IP), INC. | 2022-05-19 | — | — | US | disclosed |
| CN-113840598-A | Cannabinoid acid ester compositions and uses thereof | EPM (IP)公司 | 2021-12-24 | — | — | CN | disclosed |
| WO-2003020268-A1 | METHOD FOR THE TREATMENT AND PREVENTION OF CACHEXIA | WASHINGTON UNIVERSITY (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003015608-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020128267-A1 | Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders | PHARMACIA CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | disclosed |
| EP-1189628-A1 | COMBINATION OF TUMOR NECROSIS FACTOR (TNF) ANTAGONISTS AND COX-2 INHIBITORS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001000229-A1 | COMBINATION OF TUMORS NECROCIS FACTOR (TNF) ANTAGONISTS AND COX-2 INHIBITORS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2001-01-04 | — | — | WO | disclosed |
| US-5866596-A | DRUGS WITH ANTIINFLAMMATORY AND ANALGESIC PROPERTIES. | LABORATORIES UPSA (FR) | 1999-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192588-A1 | CANNABIDIOLIC ACID (CBDA) DERIVATIVES AND USES THEREOF | CNR2, CNR1, GPR18 | PTGS2 1908/4885PTGS1 1885/4885 |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | PTGS2 4/4885PTGS1 6/4885 |
| US-20220151972-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | CNR2, CNR1, FAAH | PTGS2 2331/4885PTGS1 2318/4885 |
| US-20260027079-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | CNR2, CNR1, FAAH | PTGS2 2555/4885PTGS1 2010/4885 |
| US-20020128267-A1 | Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885 |
| US-20230202964-A1 | CANNABIGEROLIC ACID (CDGA) DERIVATIVES AND USES THEREOF | CNR2, CNR1, GPR18 | PTGS2 411/4885PTGS1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.